November 30, 2016 - By Ruchi Gupta · 0 Comments
Quintiles Transnational Holdings Inc (NYSE:Q) institutional sentiment decreased to 0.75 in Q2 2016. Its down -0.38, from 1.13 in 2016Q1. The ratio fall, as 169 institutional investors increased and opened new holdings, while 149 trimmed and sold stakes in Quintiles Transnational Holdings Inc. The institutional investors in our partner’s database now hold: 108.59 million shares, up from 103.49 million shares in 2016Q1. Also, the number of institutional investors holding Quintiles Transnational Holdings Inc in their top 10 holdings was flat from 6 to 6 for the same number . Sold All: 39 Reduced: 110 Increased: 115 New Position: 54.
Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a well-known provider of biopharmaceutical development services and commercial outsourcing services. The company has a market cap of $19.52 billion. It is engaged in the development and commercialization of pharmaceutical therapies. It has a 24 P/E ratio. The Company’s divisions include Product Development and Integrated Healthcare Services.
About 1.27M shares traded hands. Quintiles IMS Holdings Inc (NYSE:Q) has risen 15.91% since April 27, 2016 and is uptrending. It has outperformed by 10.69% the S&P500.
Analysts await Quintiles IMS Holdings Inc (NYSE:Q) to report earnings on February, 9. They expect $1.07 EPS, up 18.89% or $0.17 from last year’s $0.9 per share. Q’s profit will be $267.12M for 18.28 P/E if the $1.07 EPS becomes a reality. After $1.00 actual EPS reported by Quintiles IMS Holdings Inc for the previous quarter, Wall Street now forecasts 7.00% EPS growth.
According to Zacks Investment Research, “Quintiles Transnational Holdings Inc. provides professional services, information and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries. The Company has two segments: Product Development and Integrated Healthcare Services. It offers project management, clinical monitoring services, strategic planning and design services, consulting services contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, brand and scientific communication, and medical education services; outcome/observational services. The Company operates in Americas, Europe and Africa, and the Asia-Pacific. Quintiles Transnational Holdings Inc. is based in Durham, North Carolina.”
3I Investments Plc holds 100% of its portfolio in Quintiles IMS Holdings Inc for 3.96 million shares. Bain Capital Investors Llc owns 9.94 million shares or 9.7% of their US portfolio. Moreover, Cryder Capital Partners Llp has 7.77% invested in the company for 148,212 shares. The New York-based Brahman Capital Corp. has invested 6.87% in the stock. Incline Global Management Llc, a New York-based fund reported 407,262 shares.#img1#
Ratings analysis reveals 40% of Quintiles Transnational’s analysts are positive. Out of 15 Wall Street analysts rating Quintiles Transnational, 6 give it “Buy”, 0 “Sell” rating, while 9 recommend “Hold”. The lowest target is $79 while the high is $95. The stock’s average target of $86.88 is 11.07% above today’s ($78.22) share price. Q was included in 21 notes of analysts from July 22, 2015. As per Wednesday, October 5, the company rating was initiated by Goldman Sachs. The firm earned “Hold” rating on Wednesday, May 4 by Evercore. The firm has “Hold” rating by Zacks given on Friday, September 4. Zacks downgraded the shares of Q in a report on Tuesday, August 25 to “Buy” rating. Zacks upgraded the shares of Q in a report on Thursday, August 20 to “Hold” rating. As per Wednesday, October 19, the company rating was downgraded by Jefferies. The stock of Quintiles IMS Holdings Inc (NYSE:Q) earned “Neutral” rating by Robert W. Baird on Wednesday, May 4. The stock of Quintiles IMS Holdings Inc (NYSE:Q) has “Hold” rating given on Thursday, August 27 by Zacks. The stock of Quintiles IMS Holdings Inc (NYSE:Q) has “Buy” rating given on Thursday, July 30 by Argus Research. The stock has “Neutral” rating given by Piper Jaffray on Thursday, October 27.
Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., incorporated on November 19, 2009, is a well-known provider of biopharmaceutical development services and commercial outsourcing services. The Firm is engaged in the development and commercialization of pharmaceutical therapies. The Company’s divisions include Product Development and Integrated Healthcare Services. The Firm offers therapeutic, scientific and analytics services to its biopharmaceutical and other healthcare customers. The Company’s Product Development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Company’s Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations. The Company’s Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.
More news for Quintiles IMS Holdings Inc (NYSE:Q) were recently published by: Streetinsider.com, which released: “Form 8-K Quintiles IMS Holdings, For: Nov 29” on November 30, 2016. Bloomberg.com‘s article titled: “IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal” and published on May 03, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta